Access Bio, Inc. (950130.KQ)

KRW 5370.0

(-2.54%)

Market Cap (In KRW)

188.88 Billion

Revenue (In KRW)

348.64 Billion

Net Income (In KRW)

-3.17 Billion

Avg. Volume

1.43 Million

Currency
KRW
Country
Open
-
Prev. Close
-
Day Range
-
Year Range
4920.0-11100.0
PE
-
EPS
-
Beta Value
-0.029
ISIN
KR8840090003
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Industry
CEO
Mr. Young-Ho Choi
Employee Count
-
Website
https://accessbio.net
Ipo Date
2013-05-30
Details
Access Bio, Inc. engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide. The company provides Covid-19 detection kits, which are tests for assessing the current or past presence of SARS-CoV-2.; rapid diagnostic tests, suitable for preliminary diagnosis or emergency medical screening in medical facilities with limited resources; analyzers, designed to measure different chemicals and other characteristics in biological samples; and molecular diagnostic solutions used in analyzing biological markers in the genome and proteome. It offers its products under CareStart, CareUS, CareSURE, and CareGENE brand names. The company was incorporated in 2002 and is headquartered in Somerset, New Jersey.